Zydus gets nod from USFDA for Saroglitazar trials |
Posted: June 6, 2016 |
Pharma company Zydus Cadila said that it has got approval from the US Food and Drug Administration (USFDA) to start clinical trials for phase II of Saroglitazar in patients with liver disease - non-alcoholic steatohepatitis (NASH).
|
|||||||||||||||||||||||||||||||||||||||
|